SETD2 and cancer: This association remained robust after adjusting for confounding factors, including age, sex, cancer type, treatment strategy, and TMB (Fig. 3c), suggesting SETD2 mutation was not a prognostic, but a predictive biomarker for cancer immunotherapy.